Back to top

Jefferies Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $104.00. Tewari ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

BioMarin Pharmaceutical Inc. (BMRN)